Sunrise, FL – Nov. 1, 2017 – U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced the opening of another regenerative clinic using its proprietary products and services, bringing the number of clinics using its technology to 287.
Regenerative Wellness Clinic (RWC), located in West Palm Beach, represents another addition to USRM’s global distribution platform for its proprietary, stem cell technology, and is a direct result of USRM’s position as the world’s largest educator in stem cell innovation and physician training, with more than 700 USRM certified stem cell physicians globally.
“We are so pleased to hit this next milestone with Regenerative Wellness, and look forward to working closely with this incredible team of experts,” said Mike Tomas, Chief Executive Officer of U.S. Stem Cell, Inc. “Partnering with RWC provides us the opportunity to expand our strategic goal of market penetration while maintaining scalability. This approach is in direct alignment with our longer-term strategy of establishing and maintaining profitability as we grow globally.”
The minimally invasive, proprietary procedure — which utilizes a patient’s own stem-cell-rich adipose or fat tissue – has, management believes, significantly boosted success rate for patient outcomes in a wide variety of indications including pain management, orthopedic, autoimmune, cardiac and other systemic conditions.
The West Palm Beach clinic is spearheaded by Dr. Rosemary Daly, an interventional spine/pain management physician, board certified in Anesthesiology and Pain Medicine. Dr. Daly graduated from the New York College of Osteopathic Medicine, and completed her Anesthesiology residency at the Montefiore Medical Center at the Albert Einstein College of Medicine.
“Being able to offer U.S. Stem Cell’s proprietary process to our patients means we will be able to make more advanced, successful regenerative treatments available to patients in South Florida,” said Dr. Daly. “Moreover, we contend that the minimally invasive treatments applied in an outpatient procedure can help jumpstart the body’s own healing capabilities and provide long-term relief — an advancement which has endless options in the world of pain management.”
“Dr. Daly’s expertise in reducing chronic and debilitating pain makes her a perfect partner for our expansion,” said Dr. Kristin Comella, Chief Science Officer for U.S. Stem Cell, Inc. “We look forward to collaborating with the excellent researchers and physicians on Dr. Daly’s team, as we continue to deepen our expertise of this ground-breaking, regenerative therapy.”
U.S. Stem Cell’s novel advancements in stem cell therapy, in managements’ opinion, could be a significant alternative to the explosive opioid crisis in America — a direct results of America’s failed attempt at pain management. According to The New York Times, published June 5, 2017, drug overdose is now the leading cause of death in the United States for patients under the age of 50, while the October 15, 2017, edition of 60 Minutes reports that the opioid crisis has claimed 200,000 lives in the United States over the past few decades.
U.S. Stem Cell, Inc. is an emerging leader in the regenerative medicine / cellular therapy industry and has, to management’s knowledge, completed more clinical treatments than any other stem cell company in the world in the past 20 years.
About U.S. Stem Cell, Inc.
U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases, ultimately, we contend, lessening patient burdens, as well as reducing the associated economic impact disease imposes upon modern society.
Our business, which includes three operating divisions (U.S. Stem Cell Training, Vetbiologics and U.S. Stem Cell Clinic) includes the development of proprietary cell therapy products, as well as revenue generating physician and patient-based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2016, and its Quarterly Reports on Form 10-Q.